| 828933-51-3 Basic information More.. |
Product Name: | nimotuzumab | Synonyms: | nimotuzumab;Research Grade Nimotuzumab(DHB86914) | CAS: | 828933-51-3 | MF: | | MW: | 0 | EINECS: | | Mol File: | Mol File | |
Use
Overexpression of epidermal growth factor receptor (EGFR), a transmembrane
receptor tyrosine kinase, is prevalent in malignant tumors of epithelial
origin and is especially common in breast, head and neck, colon, and lung cancer.
With EGFR overexpression, prognosis is poor due to associated tumor invasion,
metastasis, enhanced angiogenesis, and resistance to chemotherapy; thus,
modulation of EGFR-mediated signaling is an attractive target for intervention.
Small-molecule kinase inhibitors (gefitinib and erlotinib) and a monoclonal
antibody (cetuximab) specific for EGFR are in clinical evaluation, but treatment
cessation due to development of severe acne-like rash is common with these
EGFR antagonists. Notably, nimotuzumab, a humanized form of the murine
IgG2a monoclonal antibody that has been launched in India for treatment of head
and neck cancers overexpressing EGFR, demonstrates clinical efficacy devoid of
the rash toxicity.
.
|
828933-51-3
Recommend Suppliers |
Company Name: |
NCE Biomedical Co.,Ltd.
Recommend
Complaint |
|
Tel: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
FAX: |
+86-27-87599188 |
Email: |
|
Products Intro: |
Product Name:niMotuzuMab CAS:828933-51-3 Purity:99% HPLC Package:50Mg,100Mg,500Mg,1g,5g,10g,50g,100g,500g,1kg Remarks:XYA1241
More... |
CB Index: |
55 |
WebSite: |
www.chemicalbook.com/ShowSupplierProductsList15748/0.htm |
Related Information: |
Sales Network
Catalog(1494)
User Evaluation(2)
|
|